Pacira BioSciences (PCRX) Equity Average (2011 - 2026)

Pacira BioSciences' Equity Average history runs 16 years deep, the most recent figure standing at $673.5 million for Q1 2026.

• In Q1 2026, Equity Average fell 14.58% year-over-year to $673.5 million; the TTM figure through Mar 2026 stood at $673.5 million (down 14.58% YoY), while the FY2025 annual figure was $735.7 million, down 10.74% from the prior year.
• Equity Average was $673.5 million for Q1 2026 at Pacira BioSciences, down from $710.2 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $885.7 million in Q2 2024 to a low of $673.5 million in Q1 2026.
• Historically, Equity Average has averaged $779.8 million across 5 years, with a median of $772.6 million in 2022.
• The sharpest annual moves came in 2024 and 2026: Equity Average climbed 14.21% in 2024, then fell 14.58% in 2026.
• A 5-year view of Equity Average shows it stood at $772.6 million in 2022, then advanced by 10.13% to $850.8 million in 2023, then declined by 10.21% to $764.0 million in 2024, then retreated by 7.04% to $710.2 million in 2025, then fell by 5.16% to $673.5 million in 2026.
• The last three Equity Average figures came in at $673.5 million (Q1 2026), $710.2 million (Q4 2025), and $742.5 million (Q3 2025), per Business Quant data.